Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma.
Omalizumab (Xolair Genentech, USA/Tanox, Inc., USA/Novartis Pharma AG, Switzerland) - a humanised antibody to IgE that reduces circulating free IgE - has been developed for the treatment of allergic asthma. It inhibits the early- and late-phase response to allergens, suppresses eosinophilic and T cell inflammation in asthmatic airways and reduces the levels of high-affinity IgE receptors on basophils. In clinical trials of moderate-to-severe asthma, omalizumab allowed a reduction in inhaled corticosteroid dosage while improving peak flows and reducing exacerbations, particularly in patients at high-risk of serious asthma-related morbidity and improved quality of life scores. When added to existing therapies of patients with more severe asthma, omalizumab also improved asthma control. Additionally, in asthma patients with concomitant perennial allergic rhinitis, omalizumab provides improvement in these comorbid conditions. Omalizumab is well-tolerated by asthma patients and represents a new approach to the treatment of the moderate-to-severe asthmatic patient. It is likely that it will first be used at the more severe end of the asthmatic diathesis.
Chung
K Fan
KF
National Heart & Lung Institute, Imperial College, London, UK. f.chung@imperial.ac.uk
D000485:Allergens / Q000009:adverse effects* / Q000276:immunology; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D004341:Drug Evaluation; D006801:Humans; D000069444:Omalizumab; D016032:Randomized Controlled Trials as Topic; D012130:Respiratory Hypersensitivity / Q000188:drug therapy*
D000485:Allergens; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab